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Cancer is one of the most common causes of mortality, hence the
search for anticancer drugs has been intense. At present, most
substances, whether used in clinical applications or in experi-
mental settings, are relatively non-specific, often exerting adverse
effects on normal cells. For instance, the established and widely
used chemotherapeutic drug adriamycin (doxorubicin) is associ-
ated with cardiomyopathy consisting of congestive heart failure
and dysrhythmias, probably due to toxic effects on cardiomyo-
cytes (Henderson and Frei, 1980). Inducers of apoptosis, secreted
by cells of the immune system, including the tumour necrosis
factor-related apoptosis-inducing ligand, are toxic towards normal
cells, such as hepatocytes (Jo et al, 2000). 
We have observed recently that α -tocopheryl succinate (α -
TOS), an esterified vitamin E analogue lacking the antioxidant
activity of α -tocopherol, induced apoptosis in Jurkat T lymphoma
cells (Neuzil et al, 1999). More recently, we found α -TOS to be
pro-apoptotic for human colon cancer cells while normal skin
fibroblasts were resistant (Neuzil et al, 2001). Together with data
by others (Jha et al, 1999) suggesting a selective toxicity of α -TOS
for malignant cells, these findings prompted us to systematically
investigate this potentially important feature. Here we show that
α -TOS preferentially kills malignant cells while showing very
limited or no toxicity towards normal cells. 
MATERIALS AND METHODS 
Cell culture 
Suspension cells were maintained in RPMI-1640 supplemented
with 10% FCS plus antibiotics, adherent cells were grown in
DMEM plus 10% FCS and antibiotics, while endothelial cells
were cultures in endothelial cell medium with growth factors
(Promo Cell) and antibiotics. 
Apoptosis induction and assessment 
Apoptosis was induced by addition of 50 µM (final concentration)
of α -TOS dissolved in DMSO, controls were treated with DMSO
only. For suspension cells, cell density was 0.5 × 106 per ml at the
onset of treatment, malignant adhesion cells were treated when
70–80% confluent, while normal adhesion cells were left to grow
to confluency before treatment. 
Apoptosis was assessed in suspension cells by the annexin
V-FITC method as described earlier (Neuzil et al, 1999) and in
adherent cells by the TUNEL-FITC method according to the
manufacturer’s protocol (Boehringer, Germany). The percentage
of annexin V-positive cells was determined by flow cytometry
(Becton Dickinson) and that of TUNEL-FITC-positive cells by
scoring at least 100 cells in a fluorescent microscope. 
RESULTS AND DISCUSSION 
We studied the effect α -TOS in a wide range of cell lines and
normal cells. Strikingly, all cell lines tested were susceptible to
α -TOS, as treatment with a pharmacological dose of 50 µM for
12 h triggered apoptosis in 28–65% of the cells (Table 1). In
general, leukaemic cell lines, including monocytic and macro-
phage cell lines, B and T lymphoma cells, were more sensitive
towards  α -TOS than adherent carcinoma cell lines. Notwith-
standing,  α -TOS was pro-apoptotic towards lung, breast and
colorectal cancer cells. Moreover, α -TOS efficiently killed p53-
and p21Waf 1/Cip1
-deficient mutants of the HCT-116 colon cancer cell
line (not shown). Since mutations of tumour suppression genes
are frequent complications in cancer chemo- and radiotherapy,
this highlights the potential of α -TOS as an anticancer agent
(Kaelin, 1999). 
In contrast, normal cell types, including haematopoietic cells,
fibroblasts, endothelial cells, cardiomyocytes, hepatocytes and
smooth muscle cells, showed no susceptibility to apoptosis induced
by α -TOS. This can be exemplified by cardiomyocytes where the
effects of pro-apoptotic stimuli on morphology, cytoskeleton
and beating rate were compared. While α -TOS had no effect,
adriamycin induced morphological and cytoskeletal changes and
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mented by reports which showed no toxic effect of α -TOS on
normal fibroblasts (Jha et al, 1999) or prostate cells (Israel et al,
2000), and by a finding that α -TOS was toxic towards malignant
but protective for normal stem cells (Fariss et al, 1994). 
The reasons for the selectivity of α -TOS are not known at present.
However, the fact that it appears to affect rapidly proliferating cells is
suggestive of a role of the cell cycle in sensitivity of malignant cells to
the vitamin E analogue. We have found that pro-apoptotic activity of
α -TOS positively correlated with its inhibitory activity on protein
kinase C (PKC) (Neuzil et al, 2001), and PKC activity has been asso-
ciated with a more proliferative and invasive phenotype of malignant
cells, as shown e.g. for breast (Ways et al, 1995) or renal carcinoma
cells (Engers et al, 2000). Moreover, PKC is also involved in fast
transition through the cell cycle by regulating the cell cycle check-
point proteins p21Waf 1/Cip1
and p27Kipl (Frey et al, 1997), and α -TOS has
been shown to decrease levels of the cdk2-cyclin A complex and
increased p21Waf 1/Cip1
in a human breast cancer cell line (Turley et al,
1997). Similarly, treatment of colon cancer cells with Trolox, a water-
soluble analogue of vitamin E, led to the expression of p21Waf 1/Cip1
and
sensitization of the cells towards 5-fluorouracil (Chinery et al, 1997).
Notably, we have found that normal adherent cells which were
confluent and thus contact-arrested and quiescent were resistant to α -
TOS-induced toxicity (not shown). 
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Table 1 α -TOS induces apoptosis in transformed but not normal cells 
Cell type Apoptosisa
Control α -TOS 
Haematopoietic cell lines
NSF/N1.H7 5.7 ± 3.2 36.4 ± 4.8 
HL-60 8.1 ± 2.6 52.2 ± 7.3 
THP-1 5.1 ± 2.8 48.8 ± 8.9 
U937 8.5 ± 3.8 59.6 ± 7.9 
J774 8.1 ± 3.3 65.4 ± 9.2 
Mono Mac 6 6.2 ± 2.1 54.7 ± 7.6 
Jurkat 8.9 ± 3.1 45.2 ± 6.8 
K-562 4.5 ± 1.4 37.7 ± 5.2 
HPB 6.5 ± 2.1 35.8 ± 4.7 
REH 7.2 ± 3.8 46.9 ± 6.5 
CEM 6.5 ± 2.1 44.8 ± 7.8 
Raji 8.2 ± 2.1 56.3 ± 8.5 
Nalm-6 6.9 ± 3.5 49.6 ± 6.8 
Adenocarcinoma lung cell line
A549 1.1 ± 0.5 28.1 ± 4.2 
Breast carcinoma cell line
MCF-7 12.3 ±1.5 36.3 ± 7.3 
Bronchocarcinoma cell line
BEAS-2B 1.9 ± 1.1 36.2 ± 5.9 
Colon carcinoma cell lines
CaCo-2 6.5 ± 2.2 63.1 ± 9.8 
HCT-116 7.5 ± 1.1 37.3 ± 4.8 
HCT-15 3.5 ± 1.6 32.3 ± 4.5 
DKO-1 6.5 ± 3.1 45.2 ± 6.3 
DKO-3 6.1 ± 4.5 43.2 ± 7.1 
DKS-5 5.5 ± 3.1 41.2 ± 6.4 
DKS-8 7.2 ± 1.9 37.2 ± 5.8 
DLD-1 5.2 ± 1.8 32.3 ± 5.3 
LS1034 4.2 ± 2.6 35.9 ± 6.9 
Normal cells
Mouse peritoneal macrophages 2.1 ± 1.1 5.5 ± 3.4 
Human peripheral monocytic cells 3.5 ± 2.8 6.2 ± 4.1 
Human monocyte-derived macrophages 2.9 ± 1.5 5.2 ± 1.5 
Human skin fibroblastsb 3.5 ± 0.9 6.1 ± 2.5 
Human foreskin fibroblasts 3.8 ± 3.2 6.5 ± 4.7 
Human umbilical vein endothelial cells 3.1 ± 1.2 6.5 ± 4.2 
Rat intestinal epithelial cells 1.8 ± 1.6 3.5 ± 4.8 
Rat neonatal cardiomyocytes 1.1 ± 0.9 4.2 ± 3.1 
Rat neonatal hepatocytes 2.5 ± 1.9 4.3 ± 3.2 
Rat smooth muscle cells 2.5 ± 1.8 4.9 ± 3.2 
aApoptosis was assessed following 12-h exposure of the cells to 50 µM α -TOS. For adherent cells, the extent of apoptosis
is expressed as a sum of the corresponding values for cells that remained attached and those that detached during the
experiment. Apoptosis extent was assessed by the annexin V method for suspension cells and TUNEL staining for
adherent cells, and is expressed in % apoptotic cells as mean ± SD (n = 3–6). bNormal proliferating adherent cells were left
to reach confluence before treatment In conclusion, our results strongly suggest that α -TOS, a pharma-
cologically relevant micronutrient without known side-effects
(Bendich and Machlin, 1988), is a potent pro-apoptotic agent for a
variety of malignant cells, while being non-toxic for normal cells,
and warrants testing as an anticancer drug or adjuvant in experi-
mental animal models of tumorigenesis and leukaemia. This notion
is further encouraged by recent findings that α -TOS inhibited
tumour growth in nude mice with colon-cancer xenografts, simi-
larly or more potently than did other experimental or established
anticancer agents (Neuzil et al, 2001; Chinery et al, 1997).
Furthermore, free vitamin E or α -tocopheryl acetate, the usual phar-
macological form of vitamin E, do not have pro-apoptotic activity
(Quian et al, 1997; Neuzil et al, 1999). Hence, our results may have
important implications for therapy and prevention of cancer. 
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